Eggnovo's eggshell membrane ingredient has received Novel Food approval, marking a significant milestone in the evolution of eggshell membrane technology. This approval allows companies in Europe to use the ingredient in food supplements for the general adult population at levels up to 500 mg per day, starting July 23, 2026. The ingredient, known as egg membrane hydrolysate (enzymatically produced), is a complex matrix of proteins and bioactive compounds, offering a more accurate description of its true nature. This approval is a result of Eggnovo's scientific and technological approach, which started years ago, transforming an underutilized natural resource into a new generation of functional ingredients through biotechnology.
The approval also provides Eggnovo with five years of protection for its proprietary scientific data, giving the company exclusive rights to use the approved research supporting this ingredient until July 23, 2031, unless another company gains approval using its own independent data. This protection is crucial for the company's competitive advantage in the market.
Eggnovo's patented water-based extraction process preserves naturally occurring bioactive compounds without harsh chemicals, resulting in a water-soluble protein hydrolysate. The ingredient contains collagen types I, V, and X, as well as glucosamine, chondroitin sulfate, hyaluronic acid, glycosaminoglycans, and over 400 proteins, including those rich in sulfur-containing amino acids. Research has shown its potential in supporting joint health, skin hydration and elasticity, hair and nail strength, and general wellness.
The company's ESM-based collagen ingredients are positioned as a concentrated alternative to traditional animal-derived collagen sources, with a daily intake recommendation of approximately 300 mg, compared to higher daily quantities commonly used for some conventional collagen supplements. This makes Eggnovo's ingredients more accessible and effective for consumers.
Eggnovo's portfolio includes Ovomet for joint health applications, Ovoderm for beauty and skin-focused formulations, and Ovocet, a calcium ingredient derived from eggshells for bone health applications. The approval will allow the company to expand its technology into additional food and cosmetic sectors, where the unique properties of the ingredient may offer significant value.
The approval also opens new opportunities for functional ingredient innovation across the health and nutrition markets, making it possible to bring the clinically validated efficacy of Eggnovo's eggshell membrane ingredients into highly demanded liquid supplement formats. This will further enhance the company's position in the market and provide consumers with more effective and sustainable solutions for their health and wellness needs.
